Anavex Life Sciences Corp.
AVXL
$4.20
-$0.06-1.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.93M | 13.95M | 13.05M | 11.34M | 11.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.33M | 50.76M | 53.50M | 53.25M | 52.98M |
| Operating Income | -44.33M | -50.76M | -53.50M | -53.25M | -52.98M |
| Income Before Tax | -39.93M | -46.38M | -48.17M | -47.14M | -46.49M |
| Income Tax Expenses | 18.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.95 | -46.38 | -48.17 | -47.14 | -46.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.95M | -46.38M | -48.17M | -47.14M | -46.49M |
| EBIT | -44.33M | -50.76M | -53.50M | -53.25M | -52.98M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.46 | -0.54 | -0.57 | -0.56 | -0.55 |
| Normalized Basic EPS | -0.29 | -0.34 | -0.35 | -0.35 | -0.35 |
| EPS Diluted | -0.46 | -0.54 | -0.57 | -0.56 | -0.55 |
| Normalized Diluted EPS | -0.29 | -0.34 | -0.35 | -0.35 | -0.35 |
| Average Basic Shares Outstanding | 345.38M | 341.15M | 340.06M | 339.21M | 336.60M |
| Average Diluted Shares Outstanding | 345.38M | 341.15M | 340.06M | 339.21M | 336.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |